secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001493152-22-021835
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Q2 revenue falls 41% to $1.3M; net loss widens to $4.6M; cash $42.9M
------------------------------------------------------------------------------

- Q2 2022 revenue $1.3M vs $2.2M in Q2 2021; decrease driven by no PUR1800 revenue offset by Cipla agreement for Pulmazole.
- Net loss of $4.6M ($1.36 per share) vs $3.9M ($1.37) in Q2 2021; wider loss on lower revenue.
- Cash and equivalents $42.9M at June 30, 2022; expects to fund operations into Q2 2024.
- PUR3100 Phase 1 study dosed 23 of 24 patients; top-line data expected Q4 2022.
- Pulmazole Phase 2b study start-up initiated; patient dosing on track for Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222021835/0001493152-22-021835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222021835/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-021835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer